Breastcancer.org· @Breastcancerorg · X·· 11 hours agoScore70
Body · original
New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without the cancer growing.
🔗 Read more: https://bit.ly/4ewhPCh
#BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #Metavivor
34 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Breastcancer.org · x.com